Abstract
Status epilepticus (SE) is a major medical emergency associated with significant morbidity and mortality. SE is best defined as a continuous, generalized, convulsive seizure lasting > 5 min, or two or more seizures during which the patient does not return to baseline consciousness. The relative efficacy and safety of different drugs in the treatment of human SE should be determined in a prospective, randomized, blinded study. However, complementary animal models of SE are required to answer important questions concerning the treatment of SE because of the obvious difficulties of setting up such studies in clinical emergency conditions. This review offers an overview of the implementation and characteristics of some of the most prevalent animal models of SE currently in use. A description is also provide about how animal models of SE may facilitate the use of neurobiological techniques to successfully address critical questions in the drug treatment of SE. In particular, the experience with recently introduced drugs such as intravenous valproate will be addressed. Finally, the importance of some animal models and pharmacological approaches is explained and we discuss their impact in the development of therapeutic strategies to improve pharmacological treatment for SE is discussed.
Keywords: Epilepsy, status epilepticus, animal models, antiepileptic drugs, valproate
Current Neuropharmacology
Title: Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus
Volume: 4 Issue: 1
Author(s): E. D. Martin and M. A. Pozo
Affiliation:
Keywords: Epilepsy, status epilepticus, animal models, antiepileptic drugs, valproate
Abstract: Status epilepticus (SE) is a major medical emergency associated with significant morbidity and mortality. SE is best defined as a continuous, generalized, convulsive seizure lasting > 5 min, or two or more seizures during which the patient does not return to baseline consciousness. The relative efficacy and safety of different drugs in the treatment of human SE should be determined in a prospective, randomized, blinded study. However, complementary animal models of SE are required to answer important questions concerning the treatment of SE because of the obvious difficulties of setting up such studies in clinical emergency conditions. This review offers an overview of the implementation and characteristics of some of the most prevalent animal models of SE currently in use. A description is also provide about how animal models of SE may facilitate the use of neurobiological techniques to successfully address critical questions in the drug treatment of SE. In particular, the experience with recently introduced drugs such as intravenous valproate will be addressed. Finally, the importance of some animal models and pharmacological approaches is explained and we discuss their impact in the development of therapeutic strategies to improve pharmacological treatment for SE is discussed.
Export Options
About this article
Cite this article as:
Martin D. E. and Pozo A. M., Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus, Current Neuropharmacology 2006; 4 (1) . https://dx.doi.org/10.2174/157015906775203002
DOI https://dx.doi.org/10.2174/157015906775203002 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Nitric Oxide Signaling and the Cross Talk with Prostanoids Pathways in Vascular System
Medicinal Chemistry Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism Inhibitors of Catechol-O-methyltransferase in the Treatment of Neurological Disorders
Central Nervous System Agents in Medicinal Chemistry Study of Convolvulus pluricaulis for Antioxidant and Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Life or Death? A Physiogenomic Approach to Understand Individual Variation in Responses to Hemorrhagic Shock
Current Genomics Bedside Cardiac Pocus in Emergency Setting: A Practice Review
Reviews on Recent Clinical Trials Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Current Vascular Pharmacology Sodium Carbonate Sesquiperhydrate (2Na2CO3-3H2O2) Catalysed One-pot Synthesis of Biologically Dynamic Novel Substituted Spirooxirane Dicarboxamides
Current Catalysis Schiff Bases of Istain: Potential Anti-Leishmanial Agents
Letters in Drug Design & Discovery Organocatalyzed Heterocyclic Transformations In Green Media: A Review
Current Organocatalysis Role of the 5-HT2C Receptor in Atypical Antipsychotics: Hero or Villain?
Current Medicinal Chemistry - Central Nervous System Agents Hydrogen Sulfide-Based Therapies: Focus on H2S Releasing NSAIDs
Inflammation & Allergy - Drug Targets (Discontinued) The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression
Current Pharmaceutical Design Occurrence and Biological Activities of Eremophilane-type Sesquiterpenes
Mini-Reviews in Medicinal Chemistry Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets